Rating Change
BTIG analysts initiated coverage on Kazia Therapeutics Limited (NASDAQ:KZIA) with a Buy rating on July 01, 2026.
Rating Change BTIG analysts initiated coverage on Kazia Therapeutics Limited (NASDAQ:KZIA) with a Buy rating on July 01, 2026. Market Context Kazia Therapeutics Limited operates…

BTIG analysts initiated coverage on Kazia Therapeutics Limited (NASDAQ:KZIA) with a Buy rating on July 01, 2026.
Kazia Therapeutics Limited operates in the Healthcare sector. The stock currently trades at $14.04 with a market capitalization of $21.2M. The stock has gained 122.3% over the past 52 weeks.
Analyst coverage from BTIG provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Kazia Therapeutics Limited.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 01, 2026 | BTIG | Buy | N/A |
| Jun 11, 2026 | Lake Street | Buy | N/A |
| Apr 15, 2026 | Laidlaw & Co. | Buy | N/A |
| Jan 28, 2026 | HC Wainwright & Co. | Buy | N/A |
| Dec 12, 2025 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View KZIA Stock Page
A Buy rating from BTIG reflects the analyst's outlook on Kazia Therapeutics Limited (NASDAQ:KZIA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the KZIA forecast page.
Current market data
NASDAQ · KZIA
Keep reading